Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome
- Focus Adverse reactions
- Sponsors Lexicon Pharmaceuticals
- 12 Sep 2017 Results of pooled analysis of 5 trials (NCT02026063, NCT02063659, NCT01677910, NCT01104415, NCT00853047) presented at the 42nd European Society for Medical Oncology Congress
- 31 Mar 2016 Results from the qualitative interview study (n=11) published in the Clinical Therapeutics.
- 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.